MARKET

KMDA

KMDA

Kamada
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.92
-0.11
-1.82%
Opening 10:12 02/24 EST
OPEN
5.72
PREV CLOSE
6.03
HIGH
5.92
LOW
5.60
VOLUME
73.12K
TURNOVER
--
52 WEEK HIGH
8.00
52 WEEK LOW
4.908
MARKET CAP
263.56M
P/E (TTM)
10.76
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of KMDA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average KMDA stock price target is 9.00 with a high estimate of 11.00 and a low estimate of 7.00.

EPS

KMDA News

More
  • Kamada Ltd (KMDA) Q4 2019 Earnings Call Transcript
  • MotleyFool.com · 02/12 22:30
  • Kamada Q4 EPS $0.13, Inline, Sales $32.071M Miss $33.04M Estimate
  • Benzinga · 02/12 12:15
  • Kamada Reports Financial Results for Fourth Quarter and Fiscal Year 2019
  • GlobeNewswire · 02/12 12:00
  • Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2019 Financial Results and Host Conference Call on February 12, 2020
  • GlobeNewswire · 02/05 12:00

Industry

Pharmaceuticals
-1.84%
Pharmaceuticals & Medical Research
-1.82%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About KMDA

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.
More

Webull offers kinds of Kamada Ltd. stock information, including NASDAQ:KMDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KMDA stock news, and many more online research tools to help you make informed decisions.